The appraisal committee has prepared final draft guidance (FDG) on ublituximab for treating relapsing multiple sclerosis [ID6350] and submitted it to NICE. The FDG has been sent to consultees for this ...
There is a simple discount patient access scheme for ublituximab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback